RLFTF (RLFTF) Stock Price & Analysis
RLFTF (RLFTF) rose 3.09% to USD 0.2 as of July 25, 2026 at 12:39 UTC, according to Nexqual real-time market data.
RLFTF last closed at USD 0.19; the session ranged USD 0.24–0.24 on volume of 2,500 shares. Market capitalization is $2.53M, with a 52-week range of USD 0.16–4.88 (OQB). Source: Nexqual, July 25, 2026 at 12:39 UTC.
Key Statistics (as of July 25, 2026 at 12:39 UTC)
| Price | USD 0.2 |
|---|---|
| Change | ▲ 3.09% (up) |
| Previous Close | USD 0.19 |
| Open | USD 0.24 |
| Day Range | USD 0.24 – 0.24 |
| 52-Week Range | USD 0.16 – 4.88 |
| Volume | 2,500 shares |
| Market Cap | $2.53M |
| Exchange | OQB |
Technical Analysis (RLFTF)
Nexqual's technical model rates RLFTF "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 12:39 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 27.53 (oversold) |
| vs SMA50 | Below (USD 0.36) |
| MACD | -0.04 (negative) |
Analyst Ratings (RLFTF)
Wall Street analysts rate RLFTF "None", per Nexqual as of July 25, 2026 at 12:39 UTC.
| Consensus Rating | None |
|---|
Earnings (RLFTF)
Source: Nexqual, July 25, 2026 at 12:39 UTC.
Financials & Fundamentals (RLFTF)
| Total Revenue | $642,000 |
|---|---|
| Gross Margin | +92.06% |
| Operating Margin | -1637.85% |
| Profit Margin | +0.00% |
| ROE | -51.56% |
| Current Ratio | 1.2 |
Source: Nexqual, July 25, 2026 at 12:39 UTC.
Financial Health Score (RLFTF)
Nexqual rates RLFTF's overall financial health "Weak" across five dimensions, as of July 25, 2026 at 12:39 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — No data |
| Cash Flow | Weak — Operating cash flow -$7M |
| Efficiency | Critical — ROE -52%, ROA -25.5% |
Ownership (RLFTF)
| Insider Ownership | +48.55% |
|---|---|
| Institutional Ownership | +18.51% |
| Shares Outstanding | 12.59M |
| Float | 37.20M |
Source: Nexqual, July 25, 2026 at 12:39 UTC.
Leadership (RLFTF)
RLFTF is led by Zachery W. Henderson (age 52), CEO & Director, per Nexqual as of July 25, 2026 at 12:39 UTC.
| CEO & Director | Zachery W. Henderson (age 52) |
|---|---|
| Chief Financial Officer | Jeremy Meinen (age 36) |
| Chief Operating & Strategy Officer | Alexandre Capet (age 52) |
| Chief Technology Officer | Frédéric Condolo (age 52) |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CYDY | CytoDyn Inc. | USD 0.2 | ▲ 0% |
| RVVTF | Revive Therapeutics Ltd. | USD 0.02 | ▼ 14.29% |
| NRXP | NRX Pharmaceuticals, Inc. | USD 3.75 | ▼ 16.29% |
| OPTI | Optec International, Inc. | USD 0 | ▼ 9.09% |
| ENZC | Enzolytics Inc. | USD 0 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 12:39 UTC. This page is informational and not investment advice.